DARA-AA-001NCT07287228
The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia
StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 4 more changesShow less
- Eligibility criteria expanded, about 22 words
- Start date changed from estimate of Dec 10, 2025 to Dec 17, 2025
- Study description revised
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Overall response rate
Timeframe: Within 12 weeks after treatment
Secondary (1)
Incidence of adverse events
Arms and interventions
After enrollment, patients will receive daratumumab treatment.Experimental
This study is designed as a seamless Phase Ib/II trial. The target population is adult patients with refractory aplastic anemia (AA), who must meet the criteria for refractory AA at enrollment. After enrollment, patients will receive daratumumab treatment.
Drugs: Daratumumab
Sites
1 site in 1 country
- Institute of Hematology & Blood Diseases Hosptial, Chinese Academy of Medical Science and Peking Union Medical SchoolTianjin, Tianjin Municipality, China